"JPM26: Dexcom’s new CEO eyes international CGM markets for 2026 growth" was originally created and published by Medical ...

In his inaugural J.P. Morgan Healthcare Conference speech, newly minted Dexcom CEO Jake Leach looked to ease concerns over ...

The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...

It has been about a month since the last earnings report for DexCom (DXCM). Shares have lost about 7% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the ...

DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240605396939/en/ Diabetes management goes hands-free as ...

DexCom, Inc. (Nasdaq:DXCM), the global leader in glucose biosensing, is ushering in the next era of transformative, ...

Glucose monitoring specialist Dexcom announced it received FDA clearance for its G7 15 Day continuous glucose monitoring (CGM) system for people 18 and older with type 1, type 2 and gestational ...

SAN DIEGO--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today its next-generation Dexcom G7 CGM System ...

Please provide your email address to receive an email when new articles are posted on . People with diabetes can view data from the Dexcom G7 CGM directly on their Apple Watch without using a ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...